Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 2No longer available 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 2NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 299Neoplasms 179Breast Neoplasms 172Colorectal Neoplasms 107Neoplasm Metastasis 101Melanoma 99Multiple Myeloma 91Prostatic Neoplasms 90Ovarian Neoplasms 83Recurrence 79Carcinoma, Renal Cell 73Lung Neoplasms 71Stomach Neoplasms 67Squamous Cell Carcinoma of Head and Neck 67Lymphoma, Non-Hodgkin 60Pancreatic Neoplasms 59Leukemia, Lymphocytic, Chronic, B-Cell 56Leukemia, Myeloid, Acute 54Carcinoma, Hepatocellular 48Triple Negative Breast Neoplasms 47Small Cell Lung Carcinoma 46Urinary Bladder Neoplasms 45Lymphoma, Large B-Cell, Diffuse 43Head and Neck Neoplasms 41Endometrial Neoplasms 41Lymphoma, Follicular 39Lymphoma 37Uterine Cervical Neoplasms 35Parkinson Disease 4, Autosomal Dominant Lewy Body 35Glioblastoma 34

Interventions

Tegafur 1S 1 (combination) 1Gemcitabine 1Cisplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × INDUSTRY × Klatskin Tumor × Clear all
NCT06109779 2026-03-04

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

AstraZeneca

Phase 3 Active not recruiting
757 enrolled
Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma, Klatskin Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡